Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2018

View Archived Issues

Galapagos reports Part 1 interim results from FALCON trial of cystic fibrosis combination treatment

SCHAD role in the regulation of insulin secretion in pathogenic genetic variants and mouse models

A rare mutation in ABCC1 alters APP processing in a familial case of late-onset Alzheimer's disease

SGLT1 variants lower postprandial glucose and may protect from long-term cardiometabolic risk

USP22 controls cell cycle progression in cancer cells through CCND1 deubiquitylation

LCL-161/paclitaxel neoadjuvant trial for triple-negative breast cancers stratified by gene signature

Phase II study of the IGF-1 mimetic BVS-857 for patients with spinal and bulbar muscular atrophy

[18F]T-401, a promising PET tracer for the in vivo quantification of brain MGL occupancy

Inovio presents updated results from HVTN 098 phase I clinical study of PENNVAX-GP

First patient dosed in phase II study of CPC-634 for the treatment of ovarian cancer

Interim analysis results presented from phase IIb EMMINENCE study of MSDC-0602K

Japanese investigators patent new anti-HBV compounds

DAYBREAK phase III study of Lu-AF-35700 does not meet primary endpoint

Aerie Pharmaceuticals patents protein kinase inhibitors

U.S. researchers divulge new SCN9A blockers

Sidecar Therapeutics identifies LOXL2 and MAP3K5 inhibitors

Syndax provides updates on two entinostat trials

SpinalCyte presents 12-month data from phase I/II study of CybroCell in degenerative disc disease

Treatment initiates in first-in-human PIONEER study of GS-030

Alnylam expands Alnylam Act program and provides update on lumasiran studies

Better than Juuling: "Biochemical cigarette" resets metabolism

Fujian Guangshengtang Pharmaceutical cleared to begin clinical trials of GST-HG-161 in China

First patient dosed in MAVA long-term extension study of mavacamten

Ultragenyx to discontinue its Glut1 DS development program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...